Kwality Pharmaceuticals Limited (KPL) announced a major milestone, securing approval from the Review Committee on Genetic Manipulation (RCGM) to advance pre-clinical toxicity studies for its recombinant Erythropoietin product, 10,000 IU/mL.
Key Highlights:
- Therapeutic Application: Erythropoietin is a critical medication used to treat anemia associated with chronic kidney disease (CKD).
- Development Progress: The product has been developed in Kwality’s Biologics Unit, marking an important step in the company’s expansion into biologics.
- Future Goals: KPL is diligently working towards completing the pre-clinical studies and aims to commercialize the product in the next fiscal year.
Management Statement:
Ramesh Arora, Managing Director of Kwality Pharmaceuticals, expressed optimism about this development, emphasizing the company’s commitment to addressing critical healthcare needs through innovative biologics solutions.
This advancement strengthens Kwality Pharmaceuticals’ position in the biologics sector, underscoring its dedication to improving global healthcare.
TOPICS:
Kwality Pharmaceuticals